Amgen (AMGN) Price CAGR: History & Chart

Amgen Inc.(AMGN)

Drug Manufacturers - General · Thousand Oaks, CA

$382.47+0.00 (+0.00%)

Delayed quote: Sep 10, 2026, 4:00 PM EDT

About Amgen Inc.

Amgen Inc., established in 1980 and headquartered in Thousand Oaks, California, is a global biotechnology leader focused on discovering, developing, manufacturing, and delivering groundbreaking human medicines. The company's scientific endeavors span several critical therapeutic categories, including inflammatory conditions, oncology and hematology, bone health, cardiovascular diseases, nephrology, and neuroscience. Its extensive portfolio features a range of significant pharmaceutical products. Notable examples include Enbrel, prescribed for conditions like plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, which helps cancer patients by reducing the risk of infection linked to a low white blood cell count; Prolia, utilized in postmenopausal women to combat osteoporosis; and Xgeva, designed to prevent skeletal-related complications. Otezla offers relief for adult patients suffering from plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease. Aranesp addresses anemia and low red blood cell counts, while KYPROLIS is employed to treat patients with relapsed or refractory multiple myeloma. Furthermore, Repatha plays a vital role in lowering the incidence of major cardiovascular events such as myocardial infarction, stroke, and coronary revascularization. Amgen's comprehensive product lineup also encompasses Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. The company distributes its therapies worldwide, primarily serving healthcare providers, including physicians and their clinics, dialysis centers, hospitals, and pharmacies. Distribution is facilitated through pharmaceutical wholesale distributors, complemented by direct-to-consumer channels. Amgen actively engages in strategic collaborations. It has partnered with entities such as Novartis Pharma AG, UCB, Bayer HealthCare LLC, BeiGene, Ltd., Eli Lilly and Company, Datos Health, and Verastem, Inc., to jointly assess VS-6766 when combined with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. Another key alliance involves Kyowa Kirin Co., Ltd., for the co-development and commercialization of KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody targeting atopic dermatitis and other autoimmune conditions. Additionally, Amgen maintains research and development partnerships with Neumora Therapeutics, Inc. and Plexium, Inc.

Thousand Oaks, CA

31,500 employees

www.amgen.com

Healthcare / Drug Manufacturers - General

Sector: Healthcare
Industry: Drug Manufacturers - General
CEO: Robert A. Bradway

View full financials

Year	Start Price	End Price	Change	% Change
2026 (YTD)	$327.31	$391.27	+$63.96	+19.54%
2025	$260.64	$327.31	+$66.67	+25.58%
2024	$288.02	$260.64	−$27.38	-9.51%
2023	$262.64	$288.02	+$25.38	+9.66%
2022	$224.97	$262.64	+$37.67	+16.74%
2021	$229.92	$224.97	−$4.95	-2.15%
2020	$241.07	$229.92	−$11.15	-4.63%
2019	$194.67	$241.07	+$46.4	+23.84%
2018	$173.9	$194.67	+$20.77	+11.94%
2017	$146.21	$173.9	+$27.69	+18.94%
2016	$162.33	$146.21	−$16.12	-9.93%
2015	$159.29	$162.33	+$3.04	+1.91%
2014	$114.08	$159.29	+$45.21	+39.63%
2013	$86.2	$114.08	+$27.88	+32.34%
2012	$64.21	$86.2	+$21.99	+34.25%
2011	$54.9	$64.21	+$9.31	+16.96%
2010	$56.57	$54.9	−$1.67	-2.95%
2009	$57.75	$56.57	−$1.18	-2.04%
2008	$46.44	$57.75	+$11.31	+24.35%
2007	$68.31	$46.44	−$21.87	-32.02%
2006	$78.86	$68.31	−$10.55	-13.38%
2005	$64.15	$78.86	+$14.71	+22.93%
2004	$61.79	$64.15	+$2.36	+3.82%
2003	$48.34	$61.79	+$13.45	+27.82%
2002	$56.44	$48.34	−$8.1	-14.35%
2001	$63.94	$56.44	−$7.5	-11.73%
2000	$60.06	$63.94	+$3.88	+6.46%
1999	$26.14	$60.06	+$33.92	+129.76%
1998	$13.53	$26.14	+$12.61	+93.20%
1997	$13.59	$13.53	−$0.06	-0.44%

Year

Start Price

End Price

Change

% Change

2026 (YTD)

$327.31

$391.27

+$63.96

+19.54%

2025

$260.64

$327.31

+$66.67

+25.58%

2024

$288.02

$260.64

−$27.38

-9.51%

2023

$262.64

$288.02

+$25.38

+9.66%

2022

$224.97

$262.64

+$37.67

+16.74%

2021

$229.92

$224.97

−$4.95

-2.15%

2020

$241.07

$229.92

−$11.15

-4.63%

2019

$194.67

$241.07

+$46.4

+23.84%

2018

$173.9

$194.67

+$20.77

+11.94%

2017

$146.21

$173.9

+$27.69

+18.94%

2016

$162.33

$146.21

−$16.12

-9.93%

2015

$159.29

$162.33

+$3.04

+1.91%

2014

$114.08

$159.29

+$45.21

+39.63%

2013

$86.2

$114.08

+$27.88

+32.34%

2012

$64.21

$86.2

+$21.99

+34.25%

2011

$54.9

$64.21

+$9.31

+16.96%

2010

$56.57

$54.9

−$1.67

-2.95%

2009

$57.75

$56.57

−$1.18

-2.04%

2008

$46.44

$57.75

+$11.31

+24.35%

2007

$68.31

$46.44

−$21.87

-32.02%

2006

$78.86

$68.31

−$10.55

-13.38%

2005

$64.15

$78.86

+$14.71

+22.93%

2004

$61.79

$64.15

+$2.36

+3.82%

2003

$48.34

$61.79

+$13.45

+27.82%

2002

$56.44

$48.34

−$8.1

-14.35%

2001

$63.94

$56.44

−$7.5

-11.73%

2000

$60.06

$63.94

+$3.88

+6.46%

1999

$26.14

$60.06

+$33.92

+129.76%

1998

$13.53

$26.14

+$12.61

+93.20%

1997

$13.59

$13.53

−$0.06

-0.44%

Period	Period End	Value	QoQ Return	YoY Return
Q3 2026 (QTD)	2026-09-09	$391.27	+8.5%	+36.8%
Q2 2026	2026-06-29	$360.55	+2.1%	+24.6%
Q1 2026	2026-03-26	$353.16	+6.6%	+13.4%
Q4 2025	2025-12-22	$331.39	+15.9%	+25.3%
Q3 2025	2025-09-22	$286.00	-1.2%	-13.6%
Q2 2025	2025-06-20	$289.33	-7.1%	-9.1%

Period

Period End

Value

QoQ Return

YoY Return

Q3 2026 (QTD)

2026-09-09

$391.27

+8.5%

+36.8%

Q2 2026

2026-06-29

$360.55

+2.1%

+24.6%

Q1 2026

2026-03-26

$353.16

+6.6%

+13.4%

Q4 2025

2025-12-22

$331.39

+15.9%

+25.3%

Q3 2025

2025-09-22

$286.00

-1.2%

-13.6%

Q2 2025

2025-06-20

$289.33

-7.1%

-9.1%

Price CAGR: +8.92% (10Y, annualized)

AMGN Price CAGR Chart

AMGN Quarterly Price (YoY)

AMGN Quarterly Price

AMGN P/E Ratio

AMGN P/E Ratio Chart

AMGN Price CAGR History

Quarterly Price: QoQ & YoY

AMGN Earnings Yield

AMGN Earnings Yield Chart